- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460313
Nasopharyngeal Carriage of S. Pneumoniae
Observatory of Nasopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis and in Healthy Child - Ancillary Study for Detection of E Coli ESBL Carriers
Study Overview
Status
Intervention / Treatment
Detailed Description
Since September 2001, 121 pediatricians who are part of a research and teaching network (ACTIV) throughout France participated at this prospective study. From October to June of each subsequent year, children of both sexes suffering from suppurative acute otitis media (AOM) with fever and/or otalgia (in order to increase the probability of pneumococcal AOM), aged 6 to 24 months, were enrolled.
And a second group of healthy children aged 6 months to 15 years were also enrolled for the main study.
For ancillary study a subgroup of children were enrolled for assessment of E. coli (ESBL) resistance.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Corinne Levy, MD
- Phone Number: 0033148850404
- Email: corinne.levy@activ-france.fr
Study Contact Backup
- Name: Stéphane Béchet, MSc
- Phone Number: 0033148850404
- Email: stephane.bechet@activ-france.fr
Study Locations
-
-
-
Créteil, France
- Recruiting
- ACTIV
-
Contact:
- Corinne Levy, MD
- Phone Number: 0033148850404
- Email: corinne.levy@activ-france.fr
-
Contact:
- Stéphane Béchet, MSc
- Phone Number: 0033148850404
- Email: stephane.bechet@activ-france.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- both sexes
- suffering from suppurative AOM
- age: 6 months to 24 months for AOM
- age: 6 months to 15 years for healthy children
- informed consent from parents or guardians
Exclusion Criteria:
- Children with antibiotic treatment within 7 days before enrolment,
- severe underlying disease,
- inclusion in the study during the previous 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: prospective cohort
Nasopharyngeal sample for each enrolled children
|
Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months.
The swabs were analyzed by the French National Reference Centre for Pneumococci.
|
Other: ESBL cohort
Stool or anorectal swab samples for a subgroup of children
|
Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months.
The swabs were analyzed by the French National Reference Centre for Pneumococci.
For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
S. Pneumoniae colonisation to detect emerging serotypes
Time Frame: at inclusion
|
The percentage of children colonised by non vaccine serotypes -
|
at inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detect the emergence of resistance S. pneumoniae
Time Frame: at inclusion
|
Percentage of penicillin resistant S. pneumoniae
|
at inclusion
|
Evaluation of the rhinopharyngeal carriage of other bacteria
Time Frame: at inclusion
|
Haemophilus influenzae, Moraxella Catarrhalis, and Staphylococcus aureus in AOM group and healthy children.
|
at inclusion
|
Detect the emergence of new serotypes
Time Frame: at inclusion
|
> 10 Percent of isolated Sp, 5 percent of carrier children
|
at inclusion
|
For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.
Time Frame: at inclusion
|
Assessment of E. coli (ESBL) resistance.
|
at inclusion
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert Cohen, MD, Association Clinique Thérapeutique Infantile du val de Marne
Publications and helpful links
General Publications
- Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281.
- Rybak A, Levy C, Bonacorsi S, Bechet S, Vie le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862.
- Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865. No abstract available.
- Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Bechet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.
- Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95.
- Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52.
- Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22. No abstract available.
- Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9.
- Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423.
- Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400.
- Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Bechet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20.
- Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2.
- Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315.
- Caeymaex L, Varon E, Levy C, Bechet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213.
- Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.
- Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French.
- Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. Erratum In: Clin Infect Dis. 2008 Feb 1;46(3):489.
- Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7. doi: 10.1097/01.inf.0000243163.85163.a8.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACT0806
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Children, Only
-
Hospital Authority, Hong KongCompleted
-
Semmelweis UniversityRecruitingAnesthesia | Children, OnlyHungary
-
University of SaskatchewanCompleted
-
T.C. ORDU ÜNİVERSİTESİUnknownAdolescent | Children, Only
-
St. Justine's HospitalCompletedChildren, Only | Anesthesia; ReactionCanada
-
McMaster UniversityHamilton-Wentworth Catholic District School Board; Start2FinishCompletedPhysical Activity | Children, OnlyCanada
-
Utah State UniversityUtah Agriculture Experiment StationCompletedChildren, Only | Raman SpectroscopyUnited States
-
Children's Hospital of PhiladelphiaFood and Drug Administration (FDA)Recruiting
-
University of VirginiaCompleted
-
Victor Contreras, MSNPontificia Universidad Catolica de ChileTerminatedAnesthesia | Children, Only | ElectroencephalographyChile
Clinical Trials on nasopharyngeal sample
-
University Hospital, RouenRecruitingAsthma | Asthma in ChildrenFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Institut National de la Santé Et de la Recherche...SanofiUnknownAdult HospitalizedFrance
-
Institut National de la Santé Et de la Recherche...CompletedSevere Acute Respiratory InfectionFrance
-
GlaxoSmithKlineCompletedRespiratory DisordersUnited Kingdom
-
Institut PasteurBiogroup Laboratoire de biologie médicaleNot yet recruiting
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in...Active, not recruitingRespiratory Syncytial Virus (RSV)United Kingdom
-
Radboud University Medical CenterUnknown
-
Assistance Publique - Hôpitaux de ParisRecruitingSARS-CoV2 InfectionFrance
-
Assistance Publique - Hôpitaux de ParisPRODISS; WEEZEVENTCompleted